##plugins.themes.academic_pro.article.sidebar##
Main Article Content
Abstract
Introduction
Hyperbaric oxygen therapy (HBOT) may not be widely known. In Indonesia itself, the HBOT application was first carried out in 1960 by the Indonesian Navy Marine Health Institute / Lembaga Kesehatan Kelautan TNI AL (Lakesla) in collaboration with the Naval Central Hospital (Rumah Sakit Pusat Angkatan Laut / RSPAL) Dr. Ramelan Surabaya, where until now the facility is still the largest in Indonesia. Hyperbaric oxygen therapy was first introduced by Behnke in 1930. At that time hyperbaric oxygen therapy was only given to divers to relieve symptoms of decompression sickness (Caisson's Disease)1. Hyperbaric oxygen therapy is a treatment method using high pressure oxygen, where the pressure used is higher than atmospheric pressure (more than 1 atm). High pressure oxygen therapy methods are currently widely used as adjuvant therapy for various pathological conditions associated with hypoxic and/or ischemic conditions. The standard procedure for HBOT is to inhale pure oxygen (100% O2) using a pressure between 1.5 and 2.5 atmospheres absolute (ATA) by mask or by endotracheal tube which is the sum of the atmospheric pressure and the gauge pressure in a hyperbaric chamber2–4.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
2. Mohamed ASE, Abdelrahman AA, Aly UF, Khaled KA. Hyperbaric oxygen therapy: A review. Eur J Clin Pharm. 2018;20(5):263–9.
3. Kocaman Ürütük F. Current Approach to Hyperbaric Oxygen Therapy. Istanbul Med J. 2020;21(4):234–41.
4. Oriani G. Handbook on hyperbaric medicine. Philadelphia: Springer; 2014.
5. Raa A, Stansberg C, Steen VM, Bjerkvig R, Reed RK, Stuhr LEB. Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors. BMC Cancer. 2017;7:1–10.
6. Stuhr LEB, Raa A, Øyan AM, Kalland KH, Sakariassen PO, Petersen K, et al. Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. J Neurooncol. 2017;85(2):191–202.
7. Moen I, Oyan AM, Kalland K-H, Tronstad KJ n, Aksien LA. Hyperoxic Treatment Induces Mesenchymal-to-Epithelial Transition in a Rat Adenocarcinoma Model. BMC Cancer. 2009;4(7).
8. Moen I, Stuhr LEB. Hyperbaric oxygen therapy and cancer - A review. Target Oncol. 2020;7(4):233–42.
9. Asfar P, Singer M, Radermacher P. Understanding the benefits and harms of oxygen therapy. Intensive Care Med. 2019;41(6):1118–21.
10. Haroon A, Al-Mehdi AB, Patel M. Lung metastatic load limitation with hyperbaric oxygen. Undersea Hyperb Med Soc. 2017;34(2):78–90.
11. Daruwalla J, Christophi C. The effect of hyperbaric oxygen therapy on tumour growth in a mouse model of colorectal cancer liver metastases. Eur J Cancer. 2018;42(18):3304–11.
12. Van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutat Res - Rev Mutat Res [Internet]. 2021;728(1–2):23–34. Available from: http://dx.doi.org/10.1016/j.mrrev.2011.05.002
13. Granowitz E V., Tonomura N, Benson RM, Katz DM, Band V, Makari-Judson GP, et al. Hyperbaric oxygen inhibits benign and malignant human mammary epithelial cell proliferation. Anticancer Res. 2019;25(6 B):3833–42.
14. TB S, RL C, Hsu Y. The effect of hyperbaric oxygen on human oral cancer cells. Undersea Hyperb Med J. 2018;31(2):251.
15. Teguh DN, Levendag PC, Noever I, Voet P, van der Est H, van Rooij P, et al. Early Hyperbaric Oxygen Therapy for Reducing Radiotherapy Side Effects: Early Results of a Randomized Trial in Oropharyngeal and Nasopharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2019;75(3):711–6.
16. Gerlach NL, Barkhuysen R, Kaanders JHAM, Janssens GORJ, Sterk W, Merkx MAW. The effect of hyperbaric oxygen therapy on quality of life in oral and oropharyngeal cancer patients treated with radiotherapy. Int J Oral Maxillofac Surg. 2018;37(3):255–9.
17. Guan S, Wei J, Huang L, Wu L. Chemotherapy and chemo-resistance in nasopharyngeal carcinoma. Eur J Med Chem [Internet]. 2020;207:112758. Available from: https://doi.org/10.1016/j.ejmech.2020.112758
18. Stępień K, Ostrowski RP, Matyja E. Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours. Med Oncol. 2018;33(9):1–9.
19. Li W, Shen C, Yue X, Da L, Wang J. Hyperbaric oxygen enhanced mitochondria-targeted chemotherapy in Nasopharyngeal cancer. BMC Cancer. 2021;(October 2020).
20. Kawasoe Y, Yokouchi M, Ueno Y, Iwaya H, Yoshida H, Komiya S. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of osteosarcoma. Oncol Rep. 2017;22(5):1045–50.
21. Mayer R, Hamilton-Farrell MR, Van Der Kleij AJ, Schmutz J, Granström G, Sicko Z, et al. Hyperbaric Oxygen, Chemotherapy and Radiotherapy. Strahlentherapie und Onkol. 2015;181(2):113–23.
22. Abe M, Terashima K, Hara I, Shioyama Y, Matsuo M, Uehara S. Successf
ul hyperbaric oxygen therapy for laryngeal radionecrosis after chemoradiotherapy for mesopharyngeal cancer: Case report and literature review. Jpn J Radiol. 2017;30(4):340–4.
23. Hall SF, Groome PA, Irish J, O’Sullivan B. Radiotherapy or surgery for head and neck squamous cell cancer: Establishing the baseline for hypopharyngeal carcinoma? Cancer. 2019;115(24):5711–22.
24. Watson ER, Halnan KE, Dische S, Saunders MI, Cade IS, McEwen JB, et al. Hyperbaric oxygen and radiotherapy: A Medical Research Council trial in carcinoma of the cervix. Br J Radiol. 1978;51(611):879–87.
25. Paniello RC, Fraley PL, O’Bert R. Effect of Hyperbaric Oxygen Therapy on a Murine Squamous Cell Carcinoma Model. Head Neck. 2013;36(12):1743–6.
26. Nabil S, Nordin R, Hariri F, Mohamad Bustaman A, Syed Zainal SJ, Panicker D, et al. The use of hyperbaric oxygen therapy in head-and-neck conditions. J Head Neck Physicians Surg. 2020;8(1):27.